24 results on '"Cirilli, N."'
Search Results
2. Real life practice of sweat testing in Europe
3. A randomized placebo-controlled study on high-dose oral algal docosahexaenoic acid supplementation in children with cystic fibrosis
4. P017 Sweat test: different clinical questions require different lab reports.
5. P162 Body composition assessment in cystic fibrosis (CF) patients on elexacaftor/texacaftor/ivacaftor.
6. P129 Evidence for a role of Achromobacter xylosoxidans VBNC forms in chronic cystic fibrosis lung infection.
7. P113 Microbiology assessment in cystic fibrosis patients on elexacaftor/tezacaftor/ivacaftor.
8. P032 Sweat chloride values in cystic fibrosis patients on elexacaftor/tezacaftor/ivacaftor.
9. P007 A novel cystic fibrosis-causing mutation identified in a newborn of African origin.
10. P278 Cataloguing outcome measures of cystic fibrosis clinical studies.
11. P020 CFTR mutation panel in detecting cystic fibrosis screen positive inconclusive diagnosis patients (CFSPIDs) in the Marche Region, Italy.
12. P477 How the use of nocturnal non-invasive ventilation and oxygen therapy changes in patients with cystic fibrosis using elexacaftor/tezacaftor/ivacaftor.
13. WS10.6 Intra-individual biological variation in sweat chloride concentrations.
14. 428 Are cystic fibrosis guidelines credible? Evaluating methodological issues.
15. WS11.4 Real life practice of sweat testing in Europe: results from an ECFS-wide survey.
16. 281 Patient-centered outcomes in CF research.
17. 282 Patient priorities for research in cystic fibrosis: the IPaCOR experience.
18. P466 Yoga in children with cystic fibrosis: complementary therapy alternative to the yoga practice in the presence.
19. P348 Nutritional challenges in the era of cystic fibrosis transmembrane regulator modulators: can we still trust the body mass index?
20. 111 Non-tuberculous mycobacteria in patients with cystic fibrosis: detection and isolation from respiratory samples. Results of a cross-sectional study.
21. P413 How to use telemonitoring for the detection of respiratory exacerbations in cystic fibrosis: effectiveness and adherence.
22. 26 Risk factors for poor outcomes in cystic fibrosis newborns diagnosed by neonatal screening in Italy: years 2009–2011.
23. P207 Spirometric values and 6-minute walking distance in cystic fibrosis patients on elexacaftor/texacaftor/ivacaftor.
24. 62 Molecular diagnosis of Pseudomonas aeruginosa infection in culture-negative samples from cystic fibrosis patients.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.